Published in Carcinogenesis on December 01, 2009
Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer (2013) 1.92
Abl kinases are required for invadopodia formation and chemokine-induced invasion. J Biol Chem (2010) 1.20
Enterolobium contortisiliquum trypsin inhibitor (EcTI), a plant proteinase inhibitor, decreases in vitro cell adhesion and invasion by inhibition of Src protein-focal adhesion kinase (FAK) signaling pathways. J Biol Chem (2011) 0.89
Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol Ther (2011) 0.88
Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. Mol Cancer (2014) 0.87
Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton. Genes Cancer (2012) 0.86
Cyr61 as mediator of Src signaling in triple negative breast cancer cells. Oncotarget (2015) 0.82
CDK1-mediated phosphorylation of Abi1 attenuates Bcr-Abl-induced F-actin assembly and tyrosine phosphorylation of WAVE complex during mitosis. J Biol Chem (2011) 0.82
The Emerging Role of ABL Kinases in Solid Tumors. Trends Cancer (2015) 0.81
Regulators of Actin Dynamics in Gastrointestinal Tract Tumors. Gastroenterol Res Pract (2015) 0.78
Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci (2016) 0.78
Serum regulation of Id1 expression by a BMP pathway and BMP responsive element. Biochim Biophys Acta (2013) 0.76
GCIP functions as a tumor suppressor in non-small cell lung cancer by suppressing Id1-mediated tumor promotion. Oncotarget (2014) 0.76
[Abelson interactor 1 (Abi1) in colorectal cancer. From synaptic plasticity to tumor cell migration]. Pathologe (2013) 0.75
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev (2006) 7.92
Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature (2002) 6.26
The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol (2007) 6.00
Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol (2005) 4.75
Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol (2004) 4.35
Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat Cell Biol (2004) 4.04
Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res (2006) 3.83
Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res (2007) 3.30
Assembly and biological role of podosomes and invadopodia. Curr Opin Cell Biol (2008) 3.26
Abi, Sra1, and Kette control the stability and localization of SCAR/WAVE to regulate the formation of actin-based protrusions. Curr Biol (2003) 3.08
The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell (2005) 2.91
Wiskott-Aldrich syndrome protein regulates podosomes in primary human macrophages. Proc Natl Acad Sci U S A (1999) 2.89
An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene (1999) 2.86
EPS8 and E3B1 transduce signals from Ras to Rac. Nature (1999) 2.82
SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res (2007) 2.80
Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool (1989) 2.48
Id proteins in cell growth and tumorigenesis. Cancer Cell (2003) 2.38
Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci U S A (2004) 2.37
Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci U S A (1997) 2.35
Purification and architecture of the ubiquitous Wave complex. Proc Natl Acad Sci U S A (2004) 2.25
Abi1 regulates the activity of N-WASP and WAVE in distinct actin-based processes. Nat Cell Biol (2005) 2.16
Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proc Natl Acad Sci U S A (2005) 2.04
Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts. Cancer Res (2002) 1.96
Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res (2006) 1.96
CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol (1998) 1.93
Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J Cell Biol (2003) 1.91
Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO J (2005) 1.69
Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann N Y Acad Sci (1999) 1.68
The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol Biol Cell (2007) 1.66
Invadopodia: unique methods for measurement of extracellular matrix degradation in vitro. Methods Cell Biol (2001) 1.66
Active Rho is localized to podosomes induced by oncogenic Src and is required for their assembly and function. J Cell Biol (2004) 1.60
Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J Cell Biol (2002) 1.60
Regulation of WASP/WAVE proteins: making a long story short. J Cell Biol (2004) 1.50
Src-dependent phosphorylation of ASAP1 regulates podosomes. Mol Cell Biol (2007) 1.48
Paxillin phosphorylation controls invadopodia/podosomes spatiotemporal organization. Mol Biol Cell (2007) 1.39
Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes. Blood (1988) 1.33
v-Src SH3-enhanced interaction with focal adhesion kinase at beta 1 integrin-containing invadopodia promotes cell invasion. J Biol Chem (2002) 1.31
The SRC substrate Tks5, podosomes (invadopodia), and cancer cell invasion. Cold Spring Harb Symp Quant Biol (2005) 1.31
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev (1998) 1.27
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res (2008) 1.21
Localization and phosphorylation of Abl-interactor proteins, Abi-1 and Abi-2, in the developing nervous system. Mol Cell Neurosci (2000) 1.16
CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery. EMBO J (2007) 1.14
Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis (1998) 1.12
Abl interactor 1 binds to sos and inhibits epidermal growth factor- and v-Abl-induced activation of extracellular signal-regulated kinases. Mol Cell Biol (2000) 1.10
Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway. J Cell Sci (2007) 1.00
Invadopodia promote proteolysis of a wide variety of extracellular matrix proteins. J Cell Physiol (1994) 1.00
Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy. Breast Cancer Res Treat (1994) 0.99
Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Res (2006) 0.98
ABI-1, a human homolog to mouse Abl-interactor 1, fuses the MLL gene in acute myeloid leukemia with t(10;11)(p11.2;q23). Blood (1998) 0.93
Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion. Mol Cancer Res (2007) 0.89
Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol (2006) 1.88
FAM20: an evolutionarily conserved family of secreted proteins expressed in hematopoietic cells. BMC Genomics (2005) 1.70
Regulation of bone formation and remodeling by G-protein-coupled receptor 48. Development (2009) 1.50
Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. Am J Physiol Renal Physiol (2005) 1.26
Nanotechnology and human health: risks and benefits. J Appl Toxicol (2010) 1.15
Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate (2011) 1.11
AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol (2008) 1.11
Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol (2007) 1.09
Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol (2011) 1.06
p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol (2010) 1.06
Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med (2007) 1.05
Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway. J Cell Sci (2007) 1.00
Mapping gene expression patterns during myeloid differentiation using the EML hematopoietic progenitor cell line. Exp Hematol (2002) 0.94
Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol (2011) 0.93
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol (2003) 0.93
Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer (2005) 0.92
Dauricine induces apoptosis, inhibits proliferation and invasion through inhibiting NF-kappaB signaling pathway in colon cancer cells. J Cell Physiol (2010) 0.90
Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim (2006) 0.89
Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One (2010) 0.89
Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies? Appl Immunohistochem Mol Morphol (2007) 0.89
Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol Ther (2011) 0.88
Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Carcinogenesis (2008) 0.87
Increasing extracellular matrix collagen level and MMP activity induces cyst development in polycystic kidney disease. BMC Nephrol (2012) 0.87
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One (2011) 0.86
Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci (2007) 0.85
Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett (2011) 0.85
Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS One (2012) 0.85
Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol (2012) 0.84
Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model (2006) 0.84
Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med (2009) 0.84
Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother (2011) 0.84
Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. Cancer Immunol Immunother (2013) 0.83
Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother (2008) 0.83
Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol (2012) 0.83
Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4. BMC Cancer (2011) 0.83
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol (2015) 0.83
Practical model for psychosocial care. J Oncol Pract (2009) 0.83
Application of vitamin D and derivatives in hematological malignancies. Cancer Lett (2011) 0.82
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [corrected] induces CRM1-dependent p53 nuclear accumulation in human bronchial epithelial cells. Toxicol Sci (2010) 0.82
CDK1-mediated phosphorylation of Abi1 attenuates Bcr-Abl-induced F-actin assembly and tyrosine phosphorylation of WAVE complex during mitosis. J Biol Chem (2011) 0.82
Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther (2005) 0.81
Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol (2007) 0.81
Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model. Oncol Rep (2009) 0.81
The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J Transl Med (2008) 0.81
Antibody microarray analysis of serum glycans in esophageal squamous cell carcinoma cases and controls. Proteomics Clin Appl (2009) 0.81
The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol (2014) 0.81
CRM1-dependent p53 nuclear accumulation in lung lesions of a bitransgenic mouse lung tumor model. Oncol Rep (2011) 0.80
rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol (2008) 0.80
Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun (2008) 0.79
The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A (2007) 0.79
Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. Pancreatology (2010) 0.79
Acquired hemophilia: a case report of 2 patients with acquired factor VIII inhibitor treated with rituximab plus a short course of steroid and review of the literature. Clin Appl Thromb Hemost (2007) 0.79
Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro. Leuk Lymphoma (2011) 0.78
Repression and coactivation of CCAAT/enhancer-binding protein epsilon by sumoylation and protein inhibitor of activated STATx proteins. J Biol Chem (2005) 0.78
Curcumin modulates eukaryotic initiation factors in human lung adenocarcinoma epithelial cells. Mol Biol Rep (2009) 0.78
Genistein and hematological malignancies. Cancer Lett (2010) 0.78
Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol (2012) 0.77
Pituitary tumor transforming gene 1 in the liver. Hepatology (2006) 0.77
Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol (2014) 0.77
Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol (2015) 0.77
A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods (2007) 0.77
Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer. Chemotherapy (2016) 0.77
Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection. Curr Cancer Drug Targets (2015) 0.76
Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis. Thromb Res (2012) 0.76
Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol (2011) 0.76
Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells. Leuk Lymphoma (2010) 0.76
An update on hematological malignancies. Tex Med (2010) 0.76
G-protein coupled receptor 34 activates Erk and phosphatidylinositol 3-kinase/Akt pathways and functions as alternative pathway to mediate p185Bcr-Abl-induced transformation and leukemogenesis. Leuk Lymphoma (2014) 0.75
Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med (2008) 0.75
Immunological treatment of liver tumors. World J Gastroenterol (2005) 0.75
Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis. Int Rev Immunol (2015) 0.75
Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment? Int Rev Immunol (2011) 0.75
A clinico-pathologic correlation. Pleomorphic adenoma. J Mass Dent Soc (2009) 0.75
Epidermolysis bullosa acquisita occurring in 2 patients with hepatitis C. J Am Acad Dermatol (2006) 0.75
Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer? Clin Appl Thromb Hemost (2004) 0.75
Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemia. Eur J Haematol (2002) 0.75